The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy

被引:2
|
作者
Krol-Kulikowska, Magdalena [1 ]
Abramenko, Nikita [2 ,3 ,4 ]
Jakubek, Milan [2 ,3 ,4 ]
Banasik, Miroslaw [5 ]
Kepinska, Marta [1 ]
机构
[1] Wroclaw Med Univ, Fac Pharm, Dept Pharmaceut Biochem, Borowska 211a, PL-50556 Wroclaw, Poland
[2] Charles Univ Prague, Fac Med 1, BIOCEV, Vestec 25250, Czech Republic
[3] Charles Univ Prague, Fac Med 1, Dept Paediat & Inherited Metab Disorders, Prague 12000, Czech Republic
[4] Gen Univ Hosp, Prague 12000, Czech Republic
[5] Wroclaw Med Univ, Fac Med, Dept & Clin Nephrol & Transplantat Med, Borowska 213, PL-50556 Wroclaw, Poland
关键词
diabetes nephropathy; kidney transplant; single nucleotide polymorphisms; ACE inhibitors; molecular docking; GENE POLYMORPHISMS; DOCKING; SYSTEM;
D O I
10.3390/jcm13040995
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Angiotensin-converting enzyme (ACE) is responsible for the production of angiotensin II, and increased production of angiotensin II is observed in diabetes. What is more, ACE polymorphisms may play a role in the development of diabetic nephropathy. The aim of this study was to assess the role of selected ACE polymorphisms (rs4343 and rs4646994) in the risk of development of diabetic nephropathy and in the likelihood of renal replacement therapy. Methods: ACE polymorphisms were analyzed in a group of 225 patients who were divided into three subgroups. The rs4343 polymorphism was determined using the PCR-RFLP, and the rs4646994 polymorphism was determined using the PCR. Molecular docking between domains of ACE and its ligands was performed by using AutoDock Vina. Results: The G/G genotype of rs4343 polymorphism is associated with increased odds of developing diabetic nephropathy. The G allele is also associated with a higher risk of this disease. Similar results were obtained in patients who had already had a kidney transplant as a result of diabetic nephropathy. Conclusions: The presence of G/G and G/A genotypes, and the G allele increases the likelihood of developing diabetic nephropathy. This may also be a risk factor for renal replacement therapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Angiotensin-converting enzyme 2 polymorphisms and cardiovascular risk
    Grace, J. A.
    Burrell, L. M.
    Patel, S. K.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (10) : 1167 - 1167
  • [2] Angiotensin-Converting Enzyme (ACE) 2 Overexpression Ameliorates Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE Inhibition
    Liu, Chun Xi
    Hu, Qin
    Wang, Yan
    Zhang, Wei
    Ma, Zhi Yong
    Feng, Jin Bo
    Wang, Rong
    Wang, Xu Ping
    Dong, Bo
    Gao, Fei
    Zhang, Ming Xiang
    Zhang, Yun
    MOLECULAR MEDICINE, 2011, 17 (1-2) : 59 - 69
  • [3] Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison
    Roberto Robles, Nicolas
    Romero, Baldomero
    Fernandez-Carbonero, Enrique
    Sanchez-Casado, Emilio
    Jose Cubero, Juan
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2009, 10 (04) : 195 - 200
  • [4] Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy
    Batlle, Daniel
    Wysocki, Jan
    Soler, Maria J.
    Ranganath, Keerthi
    KIDNEY INTERNATIONAL, 2012, 81 (06) : 520 - 528
  • [5] Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients
    Aggarwal, Neerja
    Kare, Pawan Kumar
    Varshney, Parul
    Kalra, Om Prakash
    Madhu, Venkata
    Banerjee, Basu Dev
    Yadav, Anil
    Raizada, Alpana
    Tripathi, Ashok Kumar
    WORLD JOURNAL OF DIABETES, 2017, 8 (03) : 112 - 119
  • [6] Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)
    Fried, Linda F.
    Duckworth, William
    Zhang, Jane Hongyuan
    O'Connor, Theresa
    Brophy, Mar
    Emanuele, Nicholas
    Huang, Grant D.
    McCullough, Peter A.
    Palevsky, Paul M.
    Seliger, Stephen
    Warren, Stuart R.
    Peduzzi, Peter
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (02): : 361 - 368
  • [7] Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy
    Wysocki, Jan
    Ye, Minghao
    Khattab, Ahmed M.
    Fogo, Agnes
    Martin, Aline
    David, Nicolae Valentin
    Kanwar, Yashpal
    Osborn, Mark
    Batlle, Daniel
    KIDNEY INTERNATIONAL, 2017, 91 (06) : 1336 - 1346
  • [8] THE SAFETY OF ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN MODERATE HYPERTENSION
    GIRARD, M
    ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS, 1991, 10 (03): : 169 - 185
  • [9] Angiotensin-converting enzyme (ACE) I/D polymorphism is a risk factor of allergic rhinitis
    Li, P.
    Cao, L.
    Han, X.
    CELLULAR AND MOLECULAR BIOLOGY, 2017, 63 (08) : 48 - 50
  • [10] Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors
    Huang, Mao-liang
    Li, Xu
    Meng, Ying
    Xiao, Bing
    Ma, Qiang
    Ying, Song-song
    Wu, Ping-sheng
    Zhang, Zhen-shu
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (01) : e1 - e6